A new systematic review and meta-analysis of studies presented at the European Congress on Obesity in Istanbul, Turkey (May ...

GREENWICH, Conn.--(BUSINESS WIRE)--An analysis by Cedar Gate Technologies found that incretin mimetic prescription medications (also known as GLP-1 agonists) have overtaken insulin in total ...

Researchers have created a next-generation obesity drug that works like a “Trojan horse,” using GLP-1/GIP signals to slip a ...

Lifestyle intervention remains a core component of obesity management, alongside the emergence of more potent pharmacotherapy ...

With incretin-based medications such as semaglutide and tirzepatide, obesity treatment has fundamentally changed in recent years. Intervention trials have shown weight reductions of up to 20%, and for ...

A new systematic review and meta-analysis of studies presented at this year’s European Congress on Obesity in Istanbul, ...

A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for obesity and diabetes, delivering powerful weight loss while simultaneously protecting the heart, kidneys, ...

Most doses of Eli Lilly's highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year due to increased demand, according ...

For the past three years, nearly every breakthrough in obesity medicine has traced back to a single class of drugs: GLP-1 receptor agonists like semaglutide and tirzepatide. Now, a phase 2 clinical ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment ...

An experimental weight loss drug tested in mice targets five receptor systems and may reduce side effects, according to a ...